Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736494 | 0.97 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL736033 | 0.97 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL737288 | 0.97 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL28566298 | 0.94 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL738309 | 0.86 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL735577 | 0.84 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL737518 | 0.84 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL737566 | 0.84 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2006890 | 0.82 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL19312856 | 0.81 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | claimed |
| CN-1130358-C | Imidazole compound and preparation method and application thereof | SMITHKLINE BEECHAM CORP (US) | 2003-12-10 | — | — | CN | claimed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| CN-1192147-A | Imidazole compounds | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | CN | claimed |
| CN-1177959-A | Novel compounds | SMITHKLINE BEECHAM CORP (US) | 1998-04-01 | — | — | CN | claimed |
| CN-112920199-B | Piperazinone substituent or derivative thereof, preparation method and application thereof, and pharmaceutical composition | 四川大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-105189485-B | It is used as the novel propylene amide derivatives of anti-malarial agents | 埃科特莱茵药品有限公司 | 2017-10-24 | — | — | CN | disclosed |
| EP-2970217-B1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9637473-B2 | Acrylamide derivatives as antimalarial agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-02 | — | — | US | disclosed |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| EP-2970217-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0371390-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | L3MBTL3 3251/4885L3MBTL1 2929/4885MBTD1 2315/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | L3MBTL3 2714/4885L3MBTL1 2263/4885MBTD1 3244/4885 |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | RECQL, ACR, ABCC3 | L3MBTL3 4499/4885L3MBTL1 4271/4885MBTD1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.